Table 1.
Demographics of AAA patients enrolled in the MetAAA trial and longitudinal monitoring study
| Parameter | MetAAA trial cohort (n=54) | AAA monitoring cohort (n=23) | P | ||
|---|---|---|---|---|---|
| Continuous variables | n/n ♂/ ♀ | Median (IQR) | n/n ♂/ ♀ | Median (IQR) | |
| Age [years] | 44/10 | 71.00 (11.00) | 22/1 | 67.00 (14.00) | 0.218 |
| Body mass index [kg/m²] | 44/10 | 27.50 (4.84) | 22/1 | 26.78 (4.87) | 0.991 |
| Smoking pack-years [py] | 41/9 | 40.00 (32.00) | 20/1 | 40.00 (25.00) | 0.990 |
| Mean systolic blood pressure [mmHg] | 43/10 | 132.00 (15.00) | 21/1 | 130.25 (24.00) | 0.675 |
| Mean diastolic blood pressure [mmHg] | 43/10 | 79.50 (8.00) | 21/1 | 76.75 (16.00) | 0.405 |
| Maximal AAA diameter [mm] | 44/10 | 42.75 (8.90) | 22/1 | 44.60 (12.00) | 0.295 |
| Aortic segment volume [cm³] | 44/10 | 72.29 (60.63) | 22/1 | 61.57 (101.23) | 0.680 |
| Maximal ILT diameter [mm] | 42/9 | 10.80 (11.50) | 22/1 | 10.5 (10.40) | 0.578 |
| ILT volume [cm³] | 42/9 | 24.28 (40.82) | 22/1 | 24.38 (43.65) | 0.479 |
| Nominal variables | Frequency n (%) | Frequency n (%) | |||
| Sex | |||||
| Men | 44 (81.48) | 22 (95.65) | 0.106 | ||
| Women | 10 (18.52) | 1 (4.35) | |||
| Smoking | |||||
| Never | 44/10 | 4 (7.41) | 22/1 | 2 (8.70) | 0.848 |
| Past | 44/10 | 23 (42.59) | 22/1 | 12 (52.17) | 0.203 |
| Current | 44/10 | 27 (50.00) | 22/1 | 9 (39.13) | 0.286 |
| AAA family history | 44/10 | 7 (12.96) | 22/1 | 6 (26.09) | 0.396 |
| Hypertension | 44/10 | 41 (75.93) | 22/1 | 19 (82.61) | 0.751 |
| Hyperlipidemia | 44/10 | 38 (70.37) | 22/1 | 17 (73.91) | 0.977 |
| Coronary heart disease | 44/10 | 14 (25.93) | 22/1 | 8 (34.78) | 0.580 |
| Myocardial infarction | 44/10 | 9 (16.67) | 22/1 | 4 (17.39) | 0.938 |
| Stroke | 44/10 | 3 (5.56) | 22/1 | 4 (17.39) | 0.207 |
| Diabetes mellitus type II | 44/10 | 0 (0) | 22/1 | 6 (26.09) | < 0.001 |
| Peripheral artery disease | 44/10 | 13 (24.07) | 22/1 | 4 (17.39) | 0.520 |
| COPD | 44/10 | 6 (11.11) | 22/1 | 8 (34.78) | 0.014 |
| Antiplatelet therapy | 44/10 | 45 (83.33) | 22/1 | 19 (82.61) | 0.938 |
| Anticoagulation therapy | 44/10 | 13 (24.07) | 22/1 | 5 (21.74) | 0.826 |
| Antihypertensive therapy | 44/10 | 46 (85.19) | 22/1 | 20 (86.96) | 0.840 |
| Lipid-lowering agents | 44/10 | 53 (98.15) | 22/1 | 22 (95.65) | 0.531 |
| Antidiabetic medication | 44/10 | 0 (0) | 22/1 | 6 (26.09) | <0.001 |
| Metformin intake (not as IMP) | 44/10 | 0 (0) | 22/1 | 6 (26.09) | < 0.001 |
| Educational level | |||||
| Primary school | 43/8 | 3 (5.88) | 21/0 | 0 (0) | 0.256 |
| Compulsory secondary or academic secondary school (lower cycle) | 43/8 | 7 (13.73) | 21/0 | 4 (19.05) | 0.568 |
| Vocational school and apprenticeship | 43/8 | 25 (49.02) | 21/0 | 8 (38.10) | 0.398 |
| Secondary technical and higher vocational school | 43/8 | 8 (15.69) | 21/0 | 3 (14.29) | 0.881 |
| Academic secondary school (upper cycle) | 43/8 | 4 (7.84) | 21/0 | 4 (19.05) | 0.169 |
| University or university of applied sciences | 43/8 | 4 (7.84) | 21/0 | 2 (9.52) | 0.815 |
The following statistical analyses were applied: Mann–Whitney U test for continuous variables, χ2-test for nominal variables. Boldface entries indicate statistical significance.
AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; ILT, intraluminal thrombus; IMP, investigational medical product; IQR, interquartile range; n, number of individuals.